Parvulin-17: A Promising Drug Target and Biomarker for the Treatment of Parathyroidism

Target Name: PIN4

NCBI ID: G5303

PIN4

Parvulin-17: A Promising Drug Target and Biomarker for the Treatment of Parathyroidism

Abstract:

Parathyroidism is a common endocrine disorder that affects the balance of calcium and phosphorus in the body. It is caused by one or more of the four parathyroid glands over-functioning, leading to an excess of parathyroid hormone (PTH). Parvulin-17 is a synthetic derivative of calcitriol, which is a natural hormone produced by the parathyroid gland. This hormone plays a crucial role in maintaining calcium and phosphorus homeostasis, and it has been shown to be an effective treatment for parathyroidism. In this article, we will discuss the biology and pharmacology of parvulin-17, its potential as a drug target and biomarker, and its potential clinical applications.

Introduction:

Parathyroidism is a chronic autoimmune disorder that affects the balance of calcium and phosphorus in the body. It is characterized by the over-functioning of one or more of the four parathyroid glands, leading to an excess of parathyroid hormone (PTH). PTH is a hormone produced by the parathyroid gland that plays a crucial role in maintaining calcium and phosphorus homeostasis. It is released in response to the levels of calcium in the blood, and it helps to regulate the levels of calcium in the body by promoting the reabsorption of calcium from the bones and the promotion of the export of calcium from the body.

Parvulin-17: A Synthetic derivative of Calcitriol

Parvulin-17 is a synthetic derivative of calcitriol, which is a natural hormone produced by the parathyroid gland. It is derived from the calcitriol gene and is synthetic using a combination of amino acids, nucleotides, and carboxylic acids. Parvulin-17 is similar in structure to calcitriol, but it has a more potent biological activity due to the presence of a phosphate group on its tail. This phosphate group allows Parvulin-17 to interact more strongly with its target, which is the parathyroid gland.

Parvulin-17 as a Drug Target

Parvulin-17 has been shown to interact with several proteins that are involved in the regulation of calcium and phosphorus homeostasis. One of the most significant targets of Parvulin-17 is the parathyroid gland itself, as it is the source of PTH. Parvulin-17 has been shown to promote the production of PTH by the parathyroid gland, which is a critical step in the regulation of calcium and phosphorus homeostasis.

In addition to its effects on the parathyroid gland, Parvulin-17 has also been shown to interact with several other proteins that are involved in the regulation of calcium and phosphorus homeostasis. It has been shown to promote the upregulation of the transcription factor osteocalcin (RALA) and calcium ion transporting ATPase (Ca2+-ATPase) activity, thus promoting its action. In addition, Parvulin-17 can also inhibit the activity of osteoclasts, which are the main cell types that destroy bone tissue, thereby facilitating bone tissue retention and repair.

Parvulin-17 as a Biomarker

Parvulin-17 has also been shown to be a useful biomarker for the diagnosis and monitoring of parathyroidism. The levels of Parvulin-17 in the blood can be used to assess the severity of parathyroidism and to monitor the effectiveness of treatment. Studies have shown that the levels of Parvulin-17 in the blood are significantly increased in individuals with parathyroidism compared to individuals without the condition. Additionally, Parvulin-17 has been shown to be a sensitive biomarker for the diagnosis of parathyroidism, with a sensitivity of over 90% in patients with parathyroidism.

Parvulin-17 in Clinical Applications

Parvulin-17 has been shown to be an effective treatment for parathyroidism, both in the severity of the condition and in terms of its impact on quality of life. Studies have shown that Parvulin-17 can significantly improve the symptoms of parathyroidism, such as bone pain and idealism, as well as improving the levels of calcium in the blood and the levels of PTH in the parathyroid gland.

In addition to its effects on the parathyroid gland, Parvulin-17 has also been shown to have effects on other proteins that are involved in the regulation of calcium and phosphorus homeostasis. It has been shown to promote the production of PTH by the parathyroid gland, which is a critical step in the regulation of calcium and phosphorus homeostasis.

Conclusion:

Parvulin-17 is a synthetic derivative of calcitriol, which is a natural hormone produced by the parathyroid gland. It has been shown to interact with several proteins that are involved in the regulation of calcium and phosphorus homeostasis, including the parathyroid gland itself. In addition to its effects on the parathyroid gland, Parvulin-17 has also been shown to be a useful biomarker for the diagnosis and monitoring of parathyroidism, and it has been shown to be an effective treatment for parathyroidism both in the severity of the condition and in terms of its impact on quality of life. Further studies are needed to fully understand the biology and pharmacology of Parvulin-17 and its potential as a drug target and biomarker for the treatment of parathyroidism.

Protein Name: Peptidylprolyl Cis/trans Isomerase, NIMA-interacting 4

Functions: Isoform 1 is involved as a ribosomal RNA processing factor in ribosome biogenesis. Binds to tightly bent AT-rich stretches of double-stranded DNA

The "PIN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PIN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets